David Patience bought $17k of TLSI
Chief Financial Officer at TriSalus Life Sciences, Inc.. 7,100 shares at an average of $2.43, traded May 15, 2026, filed May 18, 2026.
Score components
- +22RoleCFO
- 0Trade size$17k at market
- 0Relative to holdingsHoldings up 2.6%
- +18Price context6% above the 52-week low; 64% below the 52-week high
- +15Cluster5 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-035992, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 15, 2026 | POpen-market purchase Common Stock | +7,100 | $2.43 | $17k | 275,757 | May 18, 2026 |
Related signals
Other insiders at TriSalus Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $1,299 296 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $1,427 325 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $1,387 316 shares | -0% | |
| 15Weak | TLSIsell TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $1,450 543 shares | -0% | |
| 56Moderate | TriSalus Life Sciences, Inc. | Gary B. Gordon director | $25k 10,000 shares | +16% | |
| 88Strong | TriSalus Life Sciences, Inc. | Michael P Stansky director | $1.5M 610,000 shares | +73% | |
| 73Notable | TriSalus Life Sciences, Inc. | Mary T Szela CEO and President | $103k 39,682 shares | +4% | |
| 69Notable | TriSalus Life Sciences, Inc. | Mats Wahlstrom director | $152k 60,000 shares | +69% | |
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $13k 3,184 shares | -2% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jodi Devlin Chief of Clinical Operations | $13k 3,207 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.